• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    3/3/23 12:31:10 PM ET
    $ARDX
    $BFRG
    $BMRA
    $CDNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARDX alert in real time by email

    Gainers

    • Seer (NASDAQ:SEER) shares moved upwards by 39.4% to $5.87 during Friday's regular session. As of 12:30 EST, Seer's stock is trading at a volume of 1.6 million, which is 437.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $367.7 million. The company's, Q4 earnings came out yesterday.
    • Bullfrog AI Hldgs (NASDAQ:BFRG) shares rose 39.18% to $3.8. As of 12:30 EST, Bullfrog AI Hldgs's stock is trading at a volume of 4.2 million, which is 1055.1% of its average full-day volume over the last 100 days. The company's market cap stands at $21.4 million.
    • Ardelyx (NASDAQ:ARDX) stock rose 36.18% to $3.94. Trading volume for Ardelyx's stock is 40.1 million as of 12:30 EST. This is 599.3% of its average full-day volume over the last 100 days. The company's market cap stands at $781.5 million. The company's, Q4 earnings came out yesterday.
    • Lexicon Pharmaceuticals (NASDAQ:LXRX) stock moved upwards by 18.8% to $2.59. As of 12:30 EST, this security is trading at a volume of 890.8K shares, making up 241.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $488.7 million. As per the press release, Q4 earnings came out yesterday.
    • Hillstream BioPharma (NASDAQ:HILS) stock increased by 18.55% to $1.34. Hillstream BioPharma's stock is trading at a volume of 972.5K shares as of 12:30 EST. This is 28.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $15.4 million.
    • Kala Pharmaceuticals (NASDAQ:KALA) stock rose 18.45% to $12.05. As of 12:30 EST, Kala Pharmaceuticals's stock is trading at a volume of 626.7K, which is 25.9% of its average full-day volume over the last 100 days. The company's market cap stands at $22.5 million. As per the press release, Q4 earnings came out today.

    Losers

    • Praxis Precision Medicine (NASDAQ:PRAX) stock declined by 65.2% to $1.01 during Friday's regular session. The current volume of 19.3 million shares is 1888.3% of Praxis Precision Medicine's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $53.1 million.
    • NeuroPace (NASDAQ:NPCE) stock declined by 18.22% to $3.44. Trading volume for this security as of 12:30 EST is 95.3K, which is 144.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $85.5 million. As per the news, the Q4 earnings report came out yesterday.
    • Lucira Health (NASDAQ:LHDX) shares fell 17.51% to $0.46. Lucira Health's stock is trading at a volume of 21.5 million shares as of 12:30 EST. This is 108.7% of its average full-day volume over the last 100 days. The company's market cap stands at $18.7 million.
    • Qilian Intl Hldg Gr (NASDAQ:QLI) stock fell 17.49% to $1.18. The company's market cap stands at $42.1 million.
    • Biomerica (NASDAQ:BMRA) shares declined by 16.79% to $2.31. As of 12:30 EST, this security is trading at a volume of 326.1K shares, making up 1257.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $31.1 million.
    • CareDx (NASDAQ:CDNA) stock decreased by 15.8% to $9.06. Trading volume for this security as of 12:30 EST is 7.1 million, which is 599.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $486.5 million. As per the news, the Q4 earnings report came out 4 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ARDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARDX
    $BFRG
    $BMRA
    $CDNA

    CompanyDatePrice TargetRatingAnalyst
    Praxis Precision Medicines Inc.
    $PRAX
    2/24/2026$500.00Outperform
    Wolfe Research
    Praxis Precision Medicines Inc.
    $PRAX
    2/2/2026$282.00Equal Weight
    Wells Fargo
    Ardelyx Inc.
    $ARDX
    1/9/2026Neutral → Overweight
    Piper Sandler
    CareDx Inc.
    $CDNA
    1/6/2026$26.00Buy → Hold
    Craig Hallum
    Praxis Precision Medicines Inc.
    $PRAX
    12/15/2025$250.00 → $750.00Outperform
    Oppenheimer
    Praxis Precision Medicines Inc.
    $PRAX
    11/19/2025$424.00Buy
    BTIG Research
    KALA BIO Inc.
    $KALA
    9/30/2025$1.50Outperform → Neutral
    Mizuho
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $ARDX
    $BFRG
    $BMRA
    $CDNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    10/20/23 4:37:52 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:43:04 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZA™ issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:37:08 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    $BFRG
    $BMRA
    $CDNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Praxis Precision Medicines with a new price target

    Wolfe Research initiated coverage of Praxis Precision Medicines with a rating of Outperform and set a new price target of $500.00

    2/24/26 7:55:37 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Praxis Precision Medicines with a new price target

    Wells Fargo initiated coverage of Praxis Precision Medicines with a rating of Equal Weight and set a new price target of $282.00

    2/2/26 6:51:57 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx upgraded by Piper Sandler

    Piper Sandler upgraded Ardelyx from Neutral to Overweight

    1/9/26 8:23:44 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    $BFRG
    $BMRA
    $CDNA
    SEC Filings

    View All

    SEC Form S-8 filed by Neuropace Inc.

    S-8 - NeuroPace Inc (0001528287) (Filer)

    3/3/26 5:29:33 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Neuropace Inc.

    10-K - NeuroPace Inc (0001528287) (Filer)

    3/3/26 4:54:02 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    Neuropace Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NeuroPace Inc (0001528287) (Filer)

    3/3/26 4:09:13 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $ARDX
    $BFRG
    $BMRA
    $CDNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Debbane Raymond bought $2,980 worth of shares (2,000 units at $1.49), increasing direct ownership by 0.11% to 1,906,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/27/26 8:33:21 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Debbane Raymond bought $147,000 worth of shares (100,000 units at $1.47), increasing direct ownership by 6% to 1,904,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/25/26 7:00:27 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mott David M bought $1,946,331 worth of shares (333,333 units at $5.84), increasing direct ownership by 11% to 3,302,918 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    2/23/26 9:01:11 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    $BFRG
    $BMRA
    $CDNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

    The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (Boehringer Ingelheim), Lorundrostat (Mineralys Therapeutics), Rilparencel (ProKidney), DISC-0974 (Disc Medicine), Vonsetamig (Regeneron Pharmaceuticals), and others will further boost the market growth.LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney Disease Market Insights repor

    3/3/26 5:31:00 PM ET
    $AMGN
    $IRON
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook

    -- Reported quarterly revenue of $26.6 million in Q4 2025 representing 24% growth -- -- Reiterates previously issued 2026 guidance assuming 20% to 22% growth in core RNS® revenue from existing indications, excluding any contribution from idiopathic generalized epilepsy (IGE) -- -- Continues to expect IGE contribution following potential NAUTILUS PMA-Supplement (PMA-S) approval in mid-2026 -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. Fourth Quarter 2025 Financial Highlights To

    3/3/26 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences

    THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will participate in an upcoming fireside chat at the 2026 Leerink Partners Global Healthcare Conference in Miami on Wednesday, March 11, at 10:00 a.m. Lexicon will also be participating in 1x1 investor meetings at the 2026 Jefferies Biotech on the Beach Summit, March 10–11, and at the Barclays 28th Global Healthcare Conference, March 10-12. A live recording and replay of the Leerink fireside chat can be accessed via the Events page of the Company's website at https://investors.lexpharma.com/. About Lexicon Pharmaceuticals     Lexicon is a biopharma

    3/3/26 4:01:00 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    $BFRG
    $BMRA
    $CDNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Human Resources Mcdermott Wendy converted options into 224,406 shares and covered exercise/tax liability with 68,107 shares, increasing direct ownership by 128% to 277,945 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    3/3/26 7:20:59 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Partnerships & Corp Strat Martens Rachel Yap converted options into 67,090 shares and covered exercise/tax liability with 35,826 shares (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    3/3/26 7:20:20 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Medical Officer Granowitz Craig B converted options into 312,276 shares and covered exercise/tax liability with 109,098 shares, increasing direct ownership by 169% to 323,430 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    3/3/26 7:19:33 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    $BFRG
    $BMRA
    $CDNA
    Leadership Updates

    Live Leadership Updates

    View All

    CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer

    Kennedy brings seven years of public company CFO experience CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that Keith Kennedy, the Company's Chief Operating Officer (COO), will also assume the responsibilities of Chief Financial Officer (CFO) and oversee the Company's finance organization effective February 26, 2026. Kennedy brings to CareDx over 20 years of experience and executive leadership in healthcare including global diagnostics, biopharma services, and contrac

    2/24/26 5:15:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

    BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned neurologist and epilepsy authority Dr. Orrin Devinsky, M.D., as Head of Clinical Strategy, a newly created leadership role. Dr. Devinsky is widely regarded as one of the most influential physician-scientists of his generation in modern epilepsy and clinical neuroscience. Over a career spanning more than four decades, he has shaped the development of multiple transformative therapies, built enduring global research initiatives, and helped define t

    1/13/26 4:30:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

    BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance, today announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and the promotions of Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development. "These leadership decisions reflect a deliberate evolution of Praxis as we enter a phase driven by commercial launch planning and execution readiness, late-stage developm

    1/8/26 4:45:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    $BFRG
    $BMRA
    $CDNA
    Financials

    Live finance-specific insights

    View All

    NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook

    -- Reported quarterly revenue of $26.6 million in Q4 2025 representing 24% growth -- -- Reiterates previously issued 2026 guidance assuming 20% to 22% growth in core RNS® revenue from existing indications, excluding any contribution from idiopathic generalized epilepsy (IGE) -- -- Continues to expect IGE contribution following potential NAUTILUS PMA-Supplement (PMA-S) approval in mid-2026 -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. Fourth Quarter 2025 Financial Highlights To

    3/3/26 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    Seer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors unanimously adopted a tax benefit preservation plan ("NOL Plan") designed to help preserve and protect Seer's valuable income tax net operating loss carryforwards and other tax assets ("NOLs"). As of December 31, 2025, Seer had approximately $262 million of NOLs. These NOLs, most of which are not currently subject to any expiration date, represent a valuable asset of Seer and are available to reduce Seer's future federal income tax expense. The NOL Plan is similar to those adopted by numerous o

    2/26/26 4:06:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Generated revenue of $4.2 million for the fourth quarter of 2025 and $16.6 million for the full year 2025Expanded installed base to 82 instruments, representing 67% year-over-year growth, with 33 total instruments installed during the full year 2025Seminal customer studies published in Nature and Nature Genetics highlighting the power of the Proteograph to enable clinically relevant biomarker discovery and deep biologic insigh

    2/26/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ARDX
    $BFRG
    $BMRA
    $CDNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lexicon Pharmaceuticals Inc.

    SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    12/9/24 9:33:20 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 7:53:30 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

    SC 13G/A - NeuroPace Inc (0001528287) (Subject)

    11/14/24 6:30:12 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care